Key Events This Week
8 June: Stock opens at Rs.1,005.20, down 3.62% amid broad market weakness
11 June: Valuation shifts to very attractive despite price dip to Rs.977.95
12 June: Intraday high of Rs.1,062.90 with a 7.14% surge closing at Rs.1,054.30
12 June: Week closes at Rs.1,054.30, up 1.09% for the week versus Sensex +0.57%
8 June 2026: Market Weakness Hits Stock Early in Week
Strides Pharma opened the week at Rs.1,005.20, marking a sharp decline of 3.62% from the previous Friday’s close of Rs.1,042.95. This drop outpaced the Sensex’s 1.33% fall to 34,673.90, reflecting broader market volatility impacting the stock more severely. The volume of 18,209 shares traded was relatively elevated, indicating active selling pressure amid a weak market environment.
9 June 2026: Recovery Attempt with Moderate Gains
The stock rebounded modestly on 9 June, gaining 1.25% to close at Rs.1,017.80. This recovery outperformed the Sensex’s 0.88% rise to 34,979.26, signalling some renewed investor interest. However, the volume dropped sharply to 7,873 shares, suggesting cautious participation. The stock remained below its previous week’s close, indicating ongoing uncertainty.
10 June 2026: Renewed Selling Pressure Weighs on Price
On 10 June, Strides Pharma declined 3.92% to Rs.977.95, underperforming the Sensex’s 0.61% fall to 34,766.59. The stock’s dip was accompanied by a further volume decline to 6,294 shares, reflecting subdued trading activity. This drop brought the price closer to recent lows, raising concerns about short-term momentum.
11 June 2026: Valuation Upgrade Amid Price Dip
Despite the price falling to Rs.977.95 on 11 June, down 3.92% from the prior day, the company’s valuation metrics improved significantly. Strides Pharma’s price-to-earnings ratio dropped to 15.56, substantially lower than many peers, while price-to-book value stood at 2.90. These multiples, alongside EV/EBIT and EV/EBITDA ratios of 14.61 and 11.41 respectively, positioned the stock as very attractively valued within the Pharmaceuticals & Biotechnology sector.
Return metrics were solid, with ROCE at 15.54% and ROE at 18.64%, supporting the valuation upgrade. The Mojo Score was raised to 58.0, upgrading the rating to Hold from Sell, reflecting a more balanced risk-reward profile despite short-term price weakness. The stock traded in a range of Rs.971.05 to Rs.1,029.15, remaining well above its 52-week low of Rs.769.60 but below the 52-week high of Rs.1,231.45.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
12 June 2026: Strong Intraday Surge and Weekly Close
Strides Pharma demonstrated robust strength on 12 June, surging 7.14% intraday to a high of Rs.1,062.90 and closing at Rs.1,054.30, a 6.56% gain from the previous close. This performance significantly outpaced the Sensex’s 2.20% rise to 35,342.50, highlighting the stock’s relative strength within the sector and broader market.
The stock’s price moved above its 5-day, 100-day, and 200-day moving averages, signalling short- and long-term support, although it remained below the 20-day and 50-day averages, indicating some medium-term resistance. Technical indicators such as the MACD and Bollinger Bands suggested a predominantly bullish momentum, while other oscillators showed mixed signals.
Volume surged to 17,655 shares, reflecting strong buying interest. The stock’s outperformance was notable against the Pharmaceuticals & Biotechnology sector, which lagged behind. This rally followed the valuation upgrade and rating improvement announced the previous day, suggesting growing market recognition of the stock’s improved fundamentals.
Is Strides Pharma Science Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Daily Price Comparison: Strides Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-08 | Rs.1,005.20 | -3.62% | 34,673.90 | -1.33% |
| 2026-06-09 | Rs.1,017.80 | +1.25% | 34,979.26 | +0.88% |
| 2026-06-10 | Rs.977.95 | -3.92% | 34,766.59 | -0.61% |
| 2026-06-11 | Rs.989.35 | +1.17% | 34,580.95 | -0.53% |
| 2026-06-12 | Rs.1,054.30 | +6.56% | 35,342.50 | +2.20% |
Key Takeaways
Positive Signals: The week ended with Strides Pharma outperforming the Sensex, gaining 1.09% versus the benchmark’s 0.57%. The valuation upgrade to a very attractive grade, supported by a P/E ratio of 15.56 and solid return metrics (ROCE 15.54%, ROE 18.64%), highlights the stock’s improved fundamental appeal. The strong intraday surge on 12 June, reaching Rs.1,062.90, demonstrated robust buying interest and positive technical momentum.
Cautionary Notes: The stock experienced notable volatility, with sharp declines early in the week and a recent underperformance over the prior month. Medium-term resistance remains at the 20-day and 50-day moving averages, suggesting some consolidation risk. The modest dividend yield of 0.41% may limit appeal for income-focused investors. Additionally, the small-cap classification entails higher price volatility.
Conclusion
Strides Pharma Science Ltd’s week was characterised by a volatile but ultimately positive price trajectory, supported by a significant valuation re-rating and a strong intraday rally. The stock’s relative outperformance against the Sensex and sector peers underscores its improving market perception amid broader economic uncertainties. While short-term price fluctuations and technical resistance levels warrant caution, the enhanced valuation metrics and recent rating upgrade provide a foundation for potential stability. Investors should continue to monitor earnings updates and sector developments to gauge the sustainability of this momentum.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
